[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse PTGES

Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF01124 MAPEG family
Function

Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001516 prostaglandin biosynthetic process
GO:0001676 long-chain fatty acid metabolic process
GO:0002237 response to molecule of bacterial origin
GO:0002526 acute inflammatory response
GO:0002544 chronic inflammatory response
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006692 prostanoid metabolic process
GO:0006693 prostaglandin metabolic process
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0016053 organic acid biosynthetic process
GO:0019369 arachidonic acid metabolic process
GO:0019371 cyclooxygenase pathway
GO:0032496 response to lipopolysaccharide
GO:0032526 response to retinoic acid
GO:0033559 unsaturated fatty acid metabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0046457 prostanoid biosynthetic process
GO:0051592 response to calcium ion
GO:0072330 monocarboxylic acid biosynthetic process
Molecular Function GO:0016853 isomerase activity
GO:0016860 intramolecular oxidoreductase activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0043295 glutathione binding
GO:0050220 prostaglandin-E synthase activity
GO:0072341 modified amino acid binding
GO:1900750 oligopeptide binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005635 nuclear envelope
GO:0005641 nuclear envelope lumen
GO:0031970 organelle envelope lumen
> KEGG and Reactome Pathway
 
KEGG hsa00590 Arachidonic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-2142753: Arachidonic acid metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-2162123: Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTGES and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PTGES and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29804818NeuroblastomaInhibit immunityInhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth. By specifically targeting microsomal prostaglandin E synthase-1 (mPGES-1) activity with a small molecule inhibitor we could block CAF-derived PGE2 production leading to reduced tumor growth, impaired angiogenesis, inhibited CAF migration and infiltration, reduced tumor cell proliferation and a favorable shift in the M1/M2 macrophage ratio.
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTGES in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTGES in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1010.897
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9490.528
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.850.545
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0460.934
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2240.896
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3870.858
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0560.916
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.9710.302
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9720.329
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.8320.516
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.810.633
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0510.797
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTGES in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTGES. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTGES. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTGES.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTGES. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTGES expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTGES and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTGES
Nameprostaglandin E synthase
Aliases MGST-IV; PIG12; MGST1-L1; TP53I12; microsomal glutathione S-transferase 1-like 1; tumor protein p53 inducibl ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTGES collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.